In this sense, it should be emphasized that a recent phase I/II clinical trial has demonstrated that the mTOR inhibitor everolimus was moderately effective in combination with hyper-CVAD chemotherapy especially in relapsed/refractory T-ALL patients [45]. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.